Immunologists headed by Eicke Latz (Univ. of Bonn, Germany) have found out that calorie-rich, fatty Western diet reprogrammes the innate immune system to become hyperreactive to inflammatory triggers. This could have huge medical impact as inflammation is a hallmark of most diseases of civilisation such as diabetes, cardiovascular and autoimmune disorders.
Da Volterras DAV132 helps fighting AMR crisis
Latest NewsFrench microbiota specialist Da Volterra announced that its colon-targeted adsorbent, DAV132, can protect the intestinal microbiota from disruption caused by antibiotics.
Avacta Group plc partners with Glythera
Latest NewsAntibody Drug Conjugate (ADC) specialist Glythera has licensed Actava Group’s Affimer technology in order to develop drug conjugates using the combined technologies. Affimers are small, stable synthetic proteins expressed in E.coli that mimic the molecular recognition characteristics of monoclonal antibodies.
European biotech stocks: 2017 with strong results
Latest NewsNew momentum for SMEs
BackgroundAntimicrobial resistance:?In 2017, the development of new drugs and diagnostics to combat multidrug-resistant pathogens gained momentum in Europe. Small and medium-sized companies (SMEs) successfully raised financings and grants – and some new start-ups entered the scene. To continue this trend, specific support for SMEs is needed, says the BEAM Alliance.
Western diet triggers inflammatory diseases
Latest NewsImmunologists headed by Eicke Latz (Univ. of Bonn, Germany) have found out that calorie-rich, fatty Western diet reprogrammes the innate immune system to become hyperreactive to inflammatory triggers. This could have huge medical impact as inflammation is a hallmark of most diseases of civilisation such as diabetes, cardiovascular and autoimmune disorders.
Scientists crack down immune cells that promote fibrosis
Latest NewsSo far, there is no cure to stop fibrosis, the pathogenic proliferation of connective tissue of the skin and in organs, in autoimmune diseases such as systemic sclerosis (scleroderma). An US-Italian research team has now identified the immune cells that trigger connective tissue disease.
Truffle Capital closes new BioMedTech venture fund at €85m
Latest NewsFrench venture capitalist Truffle Capital announced the first closing of its BioMedTech venture fund aimed at investments into North American and European medical devices and biotechnology start-ups.
Ablynx rejects Novo’s €2.3bn bid
Latest NewsNanobody developer Ablynx NV has stated that the take-over cash price of €28 per share + optional €2.50 per share as Contingent Value Right (CVR) offered by Novo Nordisk A/S at the end of December is too low. The bid valued Ablynx at €2.3bn.
Cancer data: a dive into the depths
BackgroundAs Big Data analytics begin to inspire medical decisionmaking, companies and scientists have gone to war over access to data derived from patient biopsies. Cancer profiling is a seminal situation. While some companies are seeking to profit from approaches to advanced mutation analysis, researchers are vociferous in demanding open access to proprietary databases behind company firewalls.
Sterna Biologicals appoints CEO
Appointmentssterna biologicals GmbH & Co. KG announced today that the Company has appointed Christian M. Pangratz as Chief Executive Officer.